Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary
نویسندگان
چکیده
BACKGROUND Mounting evidence has shown that KRAS and BRAF are somatic mutations associated with low grade serous carcinoma (LGSC) of the ovary. However, the frequency of KRAS or BRAF mutation was variable in literatures, with a frequency of 16-54% for KRAS mutation and 2-33% for BRAF mutation. Meanwhile, the prognostic significance of KRAS or BRAF mutation remains controversial. METHODS Codons 12 and 13 of exon 2 of KRAS gene and exon 15 of BRAF gene were analyzed using direct Sanger sequencing in 32 cases of LGSC of the ovary. The associations between KRAS or BRAF mutation and clinicopathological characteristics, overall survival (OS) and disease-free survival (DFS) were statistically analyzed. RESULTS KRAS mutation was observed in nine cases (9/32, 28%) and BRAF mutation in two cases (2/32, 6%). KRAS and BRAF mutations were mutually exclusive. Neither KRAS nor BRAF mutation was statistically associated with OS or DFS in our cohort, although there was a favorable prognostic trend in patients with KRAS G12D mutation than those with KRAS G12 V mutation or wild-type KRAS for OS. CONCLUSIONS The present study indicated a low frequency of BRAF or KRAS mutation in Chinese patients with LGSC of the ovary, and neither KRAS nor BRAF mutation is a prognostic factor.
منابع مشابه
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.
Activating mutations in KRAS and in one of its downstream mediators, BRAF, have been identified in a variety of human cancers. To determine the role of mutations in BRAF and KRAS in ovarian carcinoma, we analyzed both genes for three common mutations (at codon 599 of BRAF and codons 12 and 13 of KRAS). Mutations in either codon 599 of BRAF or codons 12 and 13 of KRAS occurred in 15 of 22 (68%) ...
متن کاملMutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women
PURPOSE To assess the prevalence of KRAS, BRAF, and TP53 mutations in cases of low-grade and high-grade serous carcinomas and to evaluate the clinical outcomes of these morphologically distinct carcinomas. MATERIALS AND METHODS Patients with primary invasive serous carcinomas were classified according to the universal grading system. Grade 2 serous tumors were excluded. A total of 100 patient...
متن کاملبررسی جهشهای رایج ژنهای KRAS و BRAF در بیماران مبتلا به کارسینومای بافت سنگفرشی سر و گردن
Background: Head and neck squamous cell carcinoma (HNSCC) is the malignancy of squamous cells (the epidermal layer of skin) in cavities in head and neck includes: larynx, pharynx, paranasal sinuses and oral cavity. The main goal of this research was to understand the effect of mutations in two important genes (KRAS and BRAF) in RAS/MAP kinase (EGFR) signaling pathway in tumor cells with head an...
متن کاملCase Report Significant response to trametinib in a woman with recurrent KRAS-mutated low-grade serous carcinoma of the ovary-a case report
Background: Invasive low-grade ovarian carcinomas differ from more common high-grade serous carcinomas in their pathogenesis, molecular markers, clinical behavior and response to treatment. KRAS gene mutations are present in 20 to 40 percent of low-grade serous ovarian cancer, and a smaller percentage of tumors with a wild-type KRAS carry BRAF gene mutations. As part of the RAS-RAF-MEK pathway,...
متن کاملCharacterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
PURPOSE Mitogen-activated protein kinase (MAPK) plays a pivotal role in signal transduction. Activation of MAPK is regulated by upstream kinases including KRAS and BRAF, which are frequently mutated in low-grade ovarian serous carcinoma. This study evaluates the expression of active MAPK in ovarian serous carcinomas, with response to treatment and survival. EXPERIMENTAL DESIGN Expression of a...
متن کامل